CJC-1295 — questions, answered plainly.

CJC-1295 is a synthetic 29-residue analogue of growth hormone-releasing hormone (GHRH). It has been studied in early-phase human pharmacology trials and in GHRH-knockout rodent models. It is not an approved medicine.

DAC stands for Drug Affinity Complex. The DAC modification extends the half-life of CJC-1295 by allowing covalent binding to serum albumin. The two forms have different pharmacokinetic profiles in research.

Yes — a small number of Phase I and Phase II pharmacology studies have been published, including Teichman et al. 2006 and Sackmann-Sala et al. 2009. These are early-phase trials with small cohorts and short follow-up. Long-term safety and efficacy in humans have not been established.

Growth hormone-releasing hormone is an endogenous hypothalamic peptide that stimulates the pituitary gland to secrete growth hormone. CJC-1295 is described in research as a long-acting analogue of GHRH(1–29).

The two Phase I/II human studies cited on this profile are Teichman et al. 2006 (J Clin Endocrinol Metab; PMID 16352683) and Sackmann-Sala et al. 2009 (Growth Horm IGF Res; PMID 19386527). Both are accessible via the PubMed and DOI links on the profile.

Published human studies are small Phase I/II trials. Long-term safety, efficacy for any condition, and consumer-facing claims are not established in peer-reviewed literature.